Overview

Effect of Time-of-Day (ToD) for Immunochemotherapy on PFS in NSCLC

Status:
Recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
This study aims to explore time-of-day of administration of immunochemotherapy on the efficacy for treatment naive advanced non-small cell lung cancer.
Phase:
Phase 3
Details
Lead Sponsor:
Hunan Province Tumor Hospital
Treatments:
Pembrolizumab